Celsis, the global leader in rapid microbial testing systems for industry, today introduced the Celsis Accel system, the most robust and easiest-to-use rapid microbial screening system for small and medium-size manufacturing companies.
Utilizing Celsis’ proprietary reagent technology, the Celsis Accel system reduces time necessary for quality control assessment of microbial contamination. This shortens production cycle times by lowering quarantined inventory levels awaiting quality control release and reduces working capital requirements. Faster quality control results also provide an earlier indication of contamination allowing a faster and more effective investigation and corrective action, thereby reducing the economic impact of the event.
Using its Financial Impact Assessment (FIA), Celsis works with hundreds of manufacturing facilities around the world to evaluate the cost savings of implementing a Celsis system. Utilizing company specific information including the value of products and the time and cost comparisons associated with the Celsis method, the FIA projects the 5-year Net Present Value (NPV) of a company’s investment in the Celsis system. The 5-year NPV for the average manufacturing facility is typically in excess of $300,000.
The Celsis Accel takes the robustness and ease-of-use of the widely adopted Celsis Advance platform packaged into a compact system specifically designed for small and medium-size manufacturing facilities. Easy-to-use, easy-to-learn software makes the Celsis Accel a great fit for Home, Beauty and Pharmaceutical product manufacturers’ busy microbiology labs.
“Celsis works with product manufacturers of all sizes. Small and medium-size manufacturers have different testing requirements than large manufacturers and were asking for an instrument designed to meet their needs,” said Jay LeCoque, CEO. “Responding to this demand, we developed the Accel for manufacturers whose testing requirements are smaller, but we employed the same robustness and ease-of-use of our popular large capacity Advance platform.”
To allow maximum flexibility with sample size and sensitivity, Celsis adapted the familiar sample tube platform to a precision movement carousel for easy loading and speedy processing with the ability to run 30 assays at a time. A fourth injector position gives the system flexibility to use new reagent technologies as they are developed. From reagent bottle access to sample loading, the ergonomic design puts everything easily at the fingertips of the user.
Celsis Accel.im™ takes advantage of current Celsis software innovations, such as a new ribbon menu system, data security features, and the ability to export sample results. User administration features, an event log and more allow users full compliance with the FDA’s CFR 21 Part 11 and the EU’s Annex 11.
Proven rugged and reliable systems, plus dedicated global support, have made Celsis the industry standard for leading manufacturers around the world. Celsis systems are used to rapidly and effectively screen a variety of Home, Beauty and Pharmaceutical products — including body washes, lotions, soaps, toothpastes, liquid detergents, cosmetics, tablets and ointments, IV solutions and oral drug suspensions — helping companies save time and money while releasing safe products to market.
Utilizing Celsis’ proprietary reagent technology, the Celsis Accel system reduces time necessary for quality control assessment of microbial contamination. This shortens production cycle times by lowering quarantined inventory levels awaiting quality control release and reduces working capital requirements. Faster quality control results also provide an earlier indication of contamination allowing a faster and more effective investigation and corrective action, thereby reducing the economic impact of the event.
Using its Financial Impact Assessment (FIA), Celsis works with hundreds of manufacturing facilities around the world to evaluate the cost savings of implementing a Celsis system. Utilizing company specific information including the value of products and the time and cost comparisons associated with the Celsis method, the FIA projects the 5-year Net Present Value (NPV) of a company’s investment in the Celsis system. The 5-year NPV for the average manufacturing facility is typically in excess of $300,000.
The Celsis Accel takes the robustness and ease-of-use of the widely adopted Celsis Advance platform packaged into a compact system specifically designed for small and medium-size manufacturing facilities. Easy-to-use, easy-to-learn software makes the Celsis Accel a great fit for Home, Beauty and Pharmaceutical product manufacturers’ busy microbiology labs.
“Celsis works with product manufacturers of all sizes. Small and medium-size manufacturers have different testing requirements than large manufacturers and were asking for an instrument designed to meet their needs,” said Jay LeCoque, CEO. “Responding to this demand, we developed the Accel for manufacturers whose testing requirements are smaller, but we employed the same robustness and ease-of-use of our popular large capacity Advance platform.”
To allow maximum flexibility with sample size and sensitivity, Celsis adapted the familiar sample tube platform to a precision movement carousel for easy loading and speedy processing with the ability to run 30 assays at a time. A fourth injector position gives the system flexibility to use new reagent technologies as they are developed. From reagent bottle access to sample loading, the ergonomic design puts everything easily at the fingertips of the user.
Celsis Accel.im™ takes advantage of current Celsis software innovations, such as a new ribbon menu system, data security features, and the ability to export sample results. User administration features, an event log and more allow users full compliance with the FDA’s CFR 21 Part 11 and the EU’s Annex 11.
Proven rugged and reliable systems, plus dedicated global support, have made Celsis the industry standard for leading manufacturers around the world. Celsis systems are used to rapidly and effectively screen a variety of Home, Beauty and Pharmaceutical products — including body washes, lotions, soaps, toothpastes, liquid detergents, cosmetics, tablets and ointments, IV solutions and oral drug suspensions — helping companies save time and money while releasing safe products to market.